Evidence map›Paper›PMID 41080437›Full record

ArticleEuropean clinical respiratory journal2025

Estimating the financial burden of asthma among young adults in Sweden.

Alma Holm Rovsing, Richard Ssegonja, Christer Janson, Anders Løkke, Rikke Ibsen, Ole Hilberg, Vibeke Backer, Charlotte Suppli Ulrik, Ulla Møller Weinreich, Kjell Erik Julius Håkansson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alma Holm RovsingDepartment of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark.
Richard SsegonjaDepartment of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
Christer JansonDepartment of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
Anders LøkkeDepartment of Medicine, Little Belt Hospital, Vejle, Denmark.
Rikke Ibseni2Minds, Aarhus, Denmark.
Ole HilbergDepartment of Medicine, Little Belt Hospital, Vejle, Denmark.
Vibeke BackerDepartment of Otorhinolaryngology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Charlotte Suppli UlrikDepartment of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark.
Ulla Møller WeinreichDepartment of Respiratory Diseases, Aalborg University Hospital, Aalborg, Denmark.
Kjell Erik Julius HåkanssonDepartment of Respiratory Medicine, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The financial burden of asthma in young adults remains sparsely investigated. Our study aims to estimate the Swedish national financial burden of asthma in adults aged 18-45 using nationwide databases. Methods: The financial burden of asthma in Sweden was estimated using the Swedish burden of disease, cost of medical care, and sick leave utilization data from 2022, together with healthcare consumption estimates from a nationwide burden of asthma study (data from 2014 to 2018). Costs were calculated as total costs and excess costs compared to matched controls. Results: The total annual financial burden for individuals with asthma was €3,572 per patient, divided into primary care (€929), secondary care (€1,137), medicine (€605), and sick leave transfers (€902). When compared to an age-, sex-, cohabitation-status-, and residence-matched control group, an annual excess cost of €2,299 (2,288-2,310) per patient with asthma was found. When stratified according to disease severity, patients at GINA 2020 Step 2 incurred the lowest annual cost at €2,916 (2,960-3,092), whereas GINA 2020 Step 5 represented the highest annual cost at €6,697 (6,559-6,793). Pooling the total mean costs for all young Swedish adults with ICS-treated asthma ( Conclusion: Asthma in Sweden is associated with a substantial financial burden from both direct costs and asthma-related sick leave compared to matched controls, and the pooled excess burden of ICS-treated asthma in young adults exceeded €200,000,000 annually.

Indexed as

Airway diseasechronic diseaseCostsDirect costseconomicsEuropeIndirect costsoriginal researchScandinavia

Identifiers

PMID41080437
PMCPMC12509292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.